Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright dropped their price objective on shares of Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating for the company in a report on Wednesday.

Aptose Biosciences Price Performance

NASDAQ APTO opened at $0.27 on Thursday. The company has a market cap of $4.95 million, a P/E ratio of -0.09 and a beta of 1.26. The stock has a 50-day moving average of $0.38 and a two-hundred day moving average of $0.62. Aptose Biosciences has a 1-year low of $0.27 and a 1-year high of $2.91.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Aptose Biosciences stock. Sigma Planning Corp grew its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the quarter. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 as of its most recent filing with the SEC. Institutional investors own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.